Hifas da Terra Search Biomolecules Anti-Covid-19 in the 'Digital Bio Cov' project
Marta Hifas |
What active Biomolecules Anti-Covid-19 could be present in medicinal fungi? This is the starting premise of one of the last studies of the Galician Biotech.
Hifas da Terra (HDT) receives support from the Galician Innovation Agency of the Xunta de Galicia for the realization of a R&D project focused on Prediction of anti-Covid-19 activity of new natural fractions and biomolecules of medicinal fungi.
In the future they can become natural active ingredients of new drugs to treat this complex disease.
Hifas da Terra receives support from the Galician Innovation Agency of the Xunta de Galicia for the realization of the project ‘Early prediction of anti-covid-19 activity on biomolecules present in fungi and microalgae by applying Machine Learning techniques integrating biological and chemical data (Digital Bio Cov)’ It is a study Led by HDT in collaboration with AMS Biopharma, Cifga and Plexus. The Galician company has received an economic endowment framed in the Connecta Covid program of the Galician Innovation-Xunta Agency of Galicia to R&D projects related to COVID-19, co-founded by the European Regional Development Fund (FEDER) within the Feder Galicia 2014-2020 operational program, as part of the European Union's response to the Covid-19 Pandemic.
He ‘Digital-Biocov’ projectIts objective is the integration of chemical and biological data at the bioinformatic level for the Discovery of new anti-covid-19 natural drugs.
Compounds of natural origin with anti-Covid-19 pharmacological activity
These data, obtained from laboratory tests carried out with new fractional extracts of fungi and microalgae, will allow the specific development of a prediction of anti-covid-19 activity. Through algorithms, it will be possible to predict the anti-covid-19 activity of these natural active ingredients that may be part of future treatments against this pathology.
Fungi and algae with medicinal potential
To do this, it will start from an existing collection of 150 fungiwith demonstrated medicinal potential, and more than 15 species of microalgae, from which fractions will be developed that will be subject in isolation or combined to studies of anti-covid-19 bioactivity In vitro and laboratory characterization. The resulting data will be integrated by the specific software allowing the validation of algorithms for the Early identification of active fractions against COVID-19. To maximize the success options, a kind of fungi will be included, whose extracts have provided anti-Covid-19 activity in previous studies, the compounds responsible for said activity being unknown.
What biomolecules Anti-Covid-19 have medicinal fungi
Lto integration of large amounts of Chemical and biological data They can allow an early prediction of the activity of the compounds present in fractions derived from fungi and microalgae. This would contribute to accelerating the processes and a more effective selection of fractions with potential presence of anti-Covid-19 active compounds. These strategies would also allow to explore the complexity of the synergies between different compounds that are usually responsible for greater activity. Currently, as is the case in this collaborative project led by HDT against COVID-19 supported by the Galician Innovation Agency of the Xunta de Galicia, government organs are granting each time more importance to the investigation of natural compounds with pharmacological activity, as in the case of medicinal fungi in the fight against COVID-19.
For example, recently The FDA has approved a double blind multicentric clinical trial against placebo Directed by the University of San Diego where fungal supplementation is evaluated in patients with COVID-19. Thus, it is observed that as a result to the scientific revolution that occurred in the Pandemia of 2020, the usefulness of natural assets with anti-Covid-19 activity in anti-Covid-19 is increasing contribute to the usual treatments. Among these, it is worth noting the study of medicinal fungi extracts or active biomolecules that can be isolated from these fascinating organisms, as it has been carrying out Hifas da Terra for more than 20 years.
Hifas da Terra, research as a company pillar
Hifas da Terra (HDT) is the leading biotech in Europe in the development of products based on medicinal fungi for human health. Your commitment to research, innovation and sustainability To improve health and well -being throughout the world, it translates into the development of organic nutraceutics, health products and high quality drugs and added value for the integral treatment of pathologies. Therefore, HDT allocates 62% of its R&D benefits, mainly in Gastroenterology, oncology, immunology, musculoskeletal system and mental-emotional health. Currently, the company has More than 15 active clinical studies that evaluate the benefits for the supplementation of its products, among those who stand out 2 oncological clinical trials in Colorectal cancer patients (project Micromarker), Breast cancer (project Microimmunomama), 2 highly innovative clinical trials In the area of the Women's health and clinical studies in patients with Sibo in Irritable intestine syndrome, Dao deficiency and diverticular disease, among others.Catalina Fernández de Ana Portela is responsible for the success of the Hifas Da Terra company That, like Founder and President, apply a know-how, based on more than 20 years of experience, along with a wide and international team of experts. Hifas da Terra It is a biotech that is based on research and innovation, with a high degree of specialization, on the development of Nutraceutics from medicinal fungi.
In Hifas da Terra we bet on the Innovation and scientific research offering solutions that They improve health and well -being of people through preclinical and clinical trials in which the effectiveness of our products is supported. Research Areas:
Gastroenterology
Oncology and quality of life
immunology
Musculoskeletic and mental-emotional health system
